The Gene and Cell Therapy Institute (GCTI) Spark Grant program is now open and accepting applications. Pre-proposals will be accepted until May 10, 2023. Submission information can be found on the GCTI Spark website.

The GCTI Spark grants will fund projects that can demonstrate tangible advancements towards clinical applications as well as commercialization outcomes including licensing, commercial partnerships, or new spinoff companies. The program will enhance the innovative potential of the Mass General Brigham gene and cell therapy research community, stimulate new inventive concepts, identify areas of commercially significant scientific strength, and accelerate commercialization of Mass General Brigham intellectual assets. Individual grants up to $250,000 total cost will be funded (inclusive of 20% IDC).

For FY23, the GCTI funding opportunity is open to all clinical areas and technology types that include cell or gene therapies, with a focus on research and preclinical stage programs. Multi-investigator collaborations are encouraged.

Key Dates and Information:

• Pre-proposals are due no later than May 10th, 2023 11:59pm EST
• Full proposals will be invited June 2nd, 2023
• Full proposals will be due no later than June 30th, 2023 11:59pm EST
• Full proposals selected for technology development will be announced in early August, 2023.
• The earliest possible start date is September 1, 2023.

Eligibility

• To be eligible for a GCTI Spark award, lead applicants must have PI privileges at an institution within Mass General Brigham.
• IP must be assigned to a Mass General Brigham entity.

Questions related to Gene and Cell Therapy Institute Spark Program grants policies and procedures should be emailed to the Gene and Cell Therapy Institute.

Questions related to the business opportunity should be directed to your Innovation Licensing Manager or Strategic Innovation Leader.

Click here to apply.